Literature DB >> 27168781

Effect of lysophosphatidic acid on the immune inflammatory response and the connexin 43 protein in myocardial infarction.

Duoduo Zhang1, Yan Zhang2, Chunyan Zhao3, Wenjie Zhang3, Guoguang Shao4, Hong Zhang3.   

Abstract

Lysophosphatidic acid (LPA) is an intermediate product of membrane phospholipid metabolism. Recently, LPA has gained attention for its involvement in the pathological processes of certain cardiovascular diseases. The aim of the present study was to clarify the association between the effect of LPA and the immune inflammatory response, and to investigate the effects of LPA on the protein expression levels of connexin 43 during myocardial infarction. Surface electrocardiograms of myocardial infarction rats and isolated rat heart tissue samples were obtained in order to determine the effect of LPA on the incidence of arrhythmia in rats that exhibited changes in immune status. The results demonstrated that the incidence of arrhythmia decreased when the rat immune systems were suppressed, and the incidence of arrhythmia increased when the rat immune systems were enhanced. The concentration levels of tumor necrosis factor (TNF)-α were determined by ELISA, and the results demonstrated that LPA induced T lymphocyte synthesis and TNF-α release. Using a patch-clamp technique, LPA was shown to increase the current amplitude of the voltage-dependent potassium channels (Kv) and calcium-activated potassium channels (KCa) in Jurkat T cells. The protein expression of connexin 43 (Cx43) was determined by immunohistochemical staining. The results indicated that LPA caused the degradation of Cx43 and decreased the expression of Cx43. This effect was associated with the immune status of the rats. There was a further decrease in Cx43 expression in the rats of the immune-enhanced group. To the best of our knowledge, these results provide the first evidence that LPA causes arrhythmia through the regulation of immune inflammatory cells and the decrease of Cx43 protein expression. The present study provided an experimental basis for the treatment of arrhythmia and may guide clinical care.

Entities:  

Keywords:  acute myocardial infarction; arrhythmia; connexin 43 protein; immune inflammatory response; lysophosphatidic acid

Year:  2016        PMID: 27168781      PMCID: PMC4840587          DOI: 10.3892/etm.2016.3132

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  40 in total

1.  Drug development for treatment of cardiac arrhythmias: targeting the gap junctions.

Authors:  Andrew L Wit; Heather S Duffy
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-09-21       Impact factor: 4.733

2.  Lysophosphatidic acid induces reactive oxygen species generation by activating protein kinase C in PC-3 human prostate cancer cells.

Authors:  Chu-Cheng Lin; Chuan-En Lin; Yueh-Chien Lin; Tsai-Kai Ju; Yuan-Li Huang; Ming-Shyue Lee; Jiun-Hong Chen; Hsinyu Lee
Journal:  Biochem Biophys Res Commun       Date:  2013-10-08       Impact factor: 3.575

Review 3.  Physiological significance of delayed rectifier K(+) channels (Kv1.3) expressed in T lymphocytes and their pathological significance in chronic kidney disease.

Authors:  Itsuro Kazama
Journal:  J Physiol Sci       Date:  2014-08-06       Impact factor: 2.781

Review 4.  The cellular immune system in the post-myocardial infarction repair process.

Authors:  Sam C Latet; Vicky Y Hoymans; Paul L Van Herck; Christiaan J Vrints
Journal:  Int J Cardiol       Date:  2014-11-05       Impact factor: 4.164

Review 5.  Biological roles of lysophosphatidic acid signaling through its production by autotaxin.

Authors:  Shinichi Okudaira; Hiroshi Yukiura; Junken Aoki
Journal:  Biochimie       Date:  2010-04-22       Impact factor: 4.079

6.  Involvement of the lysophosphatidic acid-generating enzyme autotaxin in lymphocyte-endothelial cell interactions.

Authors:  Tae Nakasaki; Toshiyuki Tanaka; Shinichi Okudaira; Michi Hirosawa; Eiji Umemoto; Kazuhiro Otani; Soojung Jin; Zhongbin Bai; Haruko Hayasaka; Yoshinori Fukui; Katsuyuki Aozasa; Naoya Fujita; Takashi Tsuruo; Keiichi Ozono; Junken Aoki; Masayuki Miyasaka
Journal:  Am J Pathol       Date:  2008-09-25       Impact factor: 4.307

Review 7.  Lysophosphatidic acids, cyclic phosphatidic acids and autotaxin as promising targets in therapies of cancer and other diseases.

Authors:  Edyta Gendaszewska-Darmach
Journal:  Acta Biochim Pol       Date:  2008-06-14       Impact factor: 2.149

Review 8.  Inflammation and atherosclerosis.

Authors:  Göran K Hansson; Anna-Karin L Robertson; Cecilia Söderberg-Nauclér
Journal:  Annu Rev Pathol       Date:  2006       Impact factor: 23.472

9.  LPA3 receptor mediates chemotaxis of immature murine dendritic cells to unsaturated lysophosphatidic acid (LPA).

Authors:  Liana C Chan; Wendy Peters; Yan Xu; Jerold Chun; Robert V Farese; Sylvaine Cases
Journal:  J Leukoc Biol       Date:  2007-08-20       Impact factor: 4.962

10.  Systemic inflammation and reperfusion injury in patients with acute myocardial infarction.

Authors:  Fien Blancke; Marc J Claeys; Philippe Jorens; Guy Vermeiren; Johan Bosmans; Floris L Wuyts; Chris J Vrints
Journal:  Mediators Inflamm       Date:  2005-12-14       Impact factor: 4.711

View more
  6 in total

Review 1.  Connexins in Cardiovascular and Neurovascular Health and Disease: Pharmacological Implications.

Authors:  Luc Leybaert; Paul D Lampe; Stefan Dhein; Brenda R Kwak; Peter Ferdinandy; Eric C Beyer; Dale W Laird; Christian C Naus; Colin R Green; Rainer Schulz
Journal:  Pharmacol Rev       Date:  2017-10       Impact factor: 25.468

2.  Metoprolol protects cardiomyocytes in rabbit model of heart failure by regulating Cx43.

Authors:  Hu Zhai; Wenyi Dai; Yu Wang
Journal:  Exp Ther Med       Date:  2017-12-04       Impact factor: 2.447

Review 3.  Stress, Depression, Resilience and Ageing: A Role for the LPA-LPA1 Pathway.

Authors:  Roman Dario Moreno-Fernandez; Sara Tabbai; Estela Castilla-Ortega; Margarita Perez-Martin; Guillermo Estivill-Torrus; Fernando Rodriguez de Fonseca; Luis Javier Santin; Carmen Pedraza
Journal:  Curr Neuropharmacol       Date:  2018-03-05       Impact factor: 7.363

4.  Lysophosphatidic acid enhances neointimal hyperplasia following vascular injury through modulating proliferation, autophagy, inflammation and oxidative stress.

Authors:  Xuhui Shen; Jianjun Zou; Fuyong Li; Tianhe Zhang; Tongqi Guo
Journal:  Mol Med Rep       Date:  2018-04-27       Impact factor: 2.952

5.  Lysophosphatidic Acid Is Associated With Cardiac Dysfunction and Hypertrophy by Suppressing Autophagy via the LPA3/AKT/mTOR Pathway.

Authors:  Jinjing Yang; Jiyao Xu; Xuebin Han; Hao Wang; Yuean Zhang; Jin Dong; Yongzhi Deng; Jingping Wang
Journal:  Front Physiol       Date:  2018-09-18       Impact factor: 4.566

6.  Lysophosphatidic Acid Upregulates Recepteur D'origine Nantais Expression and Cell Invasion via Egr-1, AP-1, and NF-κB Signaling in Bladder Carcinoma Cells.

Authors:  Pham Ngoc Khoi; Shinan Li; Ung Trong Thuan; Dhiraj Kumar Sah; Taek Won Kang; Thi Thinh Nguyen; Sen Lian; Yong Xia; Young Do Jung
Journal:  Int J Mol Sci       Date:  2020-01-01       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.